ARWR — ARROWHEAD PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 879407 ·
Last close
$85.60
Market Cap
$12.06B
52W High
$95.49
52W Low
$68.97
ADV30
2,797,725
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 73,737,000 | — | -141,260,000 | -132,732,000 | 2,268,265,000 | 147,531,000 | 1,669,349,000 |
| Dec 2025 | 264,033,000 | — | 40,809,000 | 30,811,000 | 1,604,181,000 | 71,370,000 | 1,041,484,000 |
| Sep 2025 | 256,472,000 | — | 44,106,000 | -23,750,000 | 1,385,295,000 | 88,706,000 | 881,879,000 |
| Jun 2025 | 27,767,000 | — | -165,550,000 | -175,241,000 | 1,380,612,000 | 129,793,000 | 860,806,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$339,305,000
Investing CF
$-229,946,000
Financing CF
$38,622,000
CapEx
$-17,298,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,596,343,000
Inventory
—
Receivables
$218,871,000
ST Investments
$845,240,000
EBIT TTM
$345,139,000
Pretax Income TTM
$254,919,000
Interest Exp TTM
$90,220,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$622,009,024
EBITDA
$-196,528,000
Free Cash Flow
$-46,121,248
Enterprise Value
$11,643,896,832
Total Cash
$1,782,190,976
Total Debt
$1,383,788,032
Shares Out
140,857,021
Trailing EPS
$-2.27
Book Value
$4.37
ROE
-42.4%
ROA
-7.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 829,448,000 | 98,346,000 | -1,631,000 | 1,385,295,000 | 881,879,000 | — | 179,552,000 |
| Sep 2024 | 3,551,000 | -601,080,000 | -599,493,000 | 1,139,802,000 | 948,739,000 | — | -462,851,000 |
| Sep 2023 | 240,735,000 | -205,002,000 | -205,275,000 | 765,552,000 | 478,390,000 | — | -153,890,000 |
| Sep 2022 | 243,231,000 | -178,507,000 | -176,063,000 | 691,939,000 | 273,600,000 | — | -136,131,000 |
TTM Snapshot
Revenues TTM
$2,500,000
NetIncome TTM
$-173,085,000
OpCashFlow TTM
$0
Assets (Latest)
$1,385,295,000
Forward EPS
$-4.56
Max Pain — expiry 2026-08-21
max pain strike: $85.00 · spot: $85.60 · call oi: 5,407 · put oi: 8,107
Expected Move to 2026-08-21:
±$10.60
(12.38%) —
implied range
$75.00 –
$96.20
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAVXF | Abivax S.A. | $12.12B | $139.00 | — |
| AXSM | Axsome Therapeutics, Inc. | $12.40B | $241.00 | — |
| ELAN | Elanco Animal Health Inc | $12.44B | $24.91 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.55B | $544.51 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.47B | $59.33 | — |
News headlines (Yahoo Finance, 1h cache)
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
2026-07-23 18:11 · Yahoo
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
2026-07-23 15:00 · Yahoo
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data
2026-07-22 22:44 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-07-22 19:48 · Yahoo
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization
2026-07-22 19:05 · Yahoo
Top Midday Gainers
2026-07-22 17:41 · Yahoo
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
2026-07-22 13:08 · Yahoo
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
2026-07-22 12:23 · Yahoo
ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients
2026-07-22 12:15 · Yahoo
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
2026-07-22 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.